Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$0.6 - $0.9 $13,228 - $19,843
-22,048 Reduced 34.96%
41,020 $37,000
Q4 2023

Jan 12, 2024

BUY
$0.65 - $0.86 $3,545 - $4,690
5,454 Added 9.47%
63,068 $48,000
Q3 2023

Oct 13, 2023

BUY
$0.65 - $1.25 $37,449 - $72,017
57,614 New
57,614 $39,000
Q3 2022

Oct 31, 2022

BUY
$0.14 - $1.33 $12,527 - $119,015
89,485 New
89,485 $108,000
Q2 2022

Jul 29, 2022

SELL
$0.88 - $1.87 $12,331 - $26,204
-14,013 Closed
0 $0
Q1 2022

Apr 29, 2022

SELL
$1.38 - $1.89 $21,340 - $29,226
-15,464 Reduced 52.46%
14,013 $25,000
Q4 2021

Feb 07, 2022

SELL
$1.51 - $2.2 $66,174 - $96,412
-43,824 Reduced 59.79%
29,477 $45,000
Q3 2021

Nov 01, 2021

BUY
$1.74 - $2.6 $127,543 - $190,582
73,301 New
73,301 $149,000

Others Institutions Holding CTXR

About Citius Pharmaceuticals, Inc.


  • Ticker CTXR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,130,000
  • Market Cap $65.8M
  • Description
  • Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...
More about CTXR
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.